|
WO2013066438A2
(en)
|
2011-07-22 |
2013-05-10 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US20150166984A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting alpha-antitrypsin point mutations
|
|
AU2015298571B2
(en)
|
2014-07-30 |
2020-09-03 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
|
US10906951B2
(en)
*
|
2015-07-29 |
2021-02-02 |
Onk Therapeutics Limited |
Modified natural killer cells and natural killer cell lines having increased cytotoxicity
|
|
EP3828266B1
(en)
*
|
2015-07-29 |
2022-11-23 |
ONK Therapeutics Limited |
Modified natural killer cells and natural killer cell lines having increased cytotoxicity
|
|
EP4339287A3
(en)
*
|
2015-07-31 |
2024-05-22 |
Regents Of The University Of Minnesota |
Modified cells and methods of therapy
|
|
WO2017070632A2
(en)
|
2015-10-23 |
2017-04-27 |
President And Fellows Of Harvard College |
Nucleobase editors and uses thereof
|
|
WO2017083441A1
(en)
*
|
2015-11-09 |
2017-05-18 |
Aperisys, Inc. |
Modified immune cells and uses thereof
|
|
WO2017180587A2
(en)
|
2016-04-11 |
2017-10-19 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
WO2017214569A1
(en)
*
|
2016-06-09 |
2017-12-14 |
Regents Of The University Of Minnesota |
Genome-edited nk cell and methods of making and using
|
|
US11466291B2
(en)
*
|
2016-07-06 |
2022-10-11 |
Cellectis |
Sequential gene editing in primary immune cells
|
|
WO2018027078A1
(en)
|
2016-08-03 |
2018-02-08 |
President And Fellows Of Harard College |
Adenosine nucleobase editors and uses thereof
|
|
AU2017308889B2
(en)
|
2016-08-09 |
2023-11-09 |
President And Fellows Of Harvard College |
Programmable Cas9-recombinase fusion proteins and uses thereof
|
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
US10724043B2
(en)
|
2016-10-06 |
2020-07-28 |
Nantbio, Inc. |
Multi-pulse transfection methods and cells
|
|
KR20240007715A
(ko)
|
2016-10-14 |
2024-01-16 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵염기 에디터의 aav 전달
|
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
|
WO2018126074A1
(en)
*
|
2016-12-30 |
2018-07-05 |
Celularity, Inc. |
Genetically modified natural killer cells
|
|
AU2018219895C1
(en)
*
|
2017-02-09 |
2024-10-03 |
Indapta Therapeutics, Inc. |
Engineered Natural Killer (NK) cells and compositions and methods thereof
|
|
SG11201908472VA
(en)
*
|
2017-02-15 |
2019-10-30 |
Univ California |
Compositions and methods for activating nk cells
|
|
KR20190123328A
(ko)
|
2017-03-09 |
2019-10-31 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
암 백신
|
|
WO2018165504A1
(en)
|
2017-03-09 |
2018-09-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
|
CN110914310A
(zh)
|
2017-03-10 |
2020-03-24 |
哈佛大学的校长及成员们 |
胞嘧啶至鸟嘌呤碱基编辑器
|
|
IL306092A
(en)
|
2017-03-23 |
2023-11-01 |
Harvard College |
Nucleic base editors that include nucleic acid programmable DNA binding proteins
|
|
KR20190141695A
(ko)
*
|
2017-04-13 |
2019-12-24 |
센티 바이오사이언시스, 인코포레이티드 |
병용 암 면역요법
|
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
|
IL270776B2
(en)
*
|
2017-05-25 |
2024-11-01 |
Bluebird Bio Inc |
Cblb endonuclease variants, compositions, and methods of use
|
|
PE20241587A1
(es)
|
2017-06-02 |
2024-08-01 |
Pfizer |
Receptores de antigenos quimericos que se dirigen a flt3
|
|
WO2019016360A1
(en)
*
|
2017-07-21 |
2019-01-24 |
Cellectis |
MODIFIED IMMUNE CELLS RESISTANT TO TUMOR MICRO-ENVIRONMENT
|
|
CA3069557A1
(en)
*
|
2017-07-21 |
2019-01-24 |
Cellectis |
Engineered immune cells resistant to tumor microoenvironment
|
|
EP3658573A1
(en)
|
2017-07-28 |
2020-06-03 |
President and Fellows of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
|
|
EP3441461A1
(en)
*
|
2017-08-11 |
2019-02-13 |
Baylor College of Medicine |
Cd1d-restricted nkt cells as a platform for off-the-shelf cancer immunotherapy
|
|
EP3676376B1
(en)
|
2017-08-30 |
2025-01-15 |
President and Fellows of Harvard College |
High efficiency base editors comprising gam
|
|
CA3082251A1
(en)
|
2017-10-16 |
2019-04-25 |
The Broad Institute, Inc. |
Uses of adenosine base editors
|
|
WO2019077037A1
(en)
*
|
2017-10-18 |
2019-04-25 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
METHODS AND COMPOUNDS FOR ENHANCED IMMUNE CELL THERAPY
|
|
JP2021502077A
(ja)
*
|
2017-11-06 |
2021-01-28 |
エディタス・メディシン，インコーポレイテッド |
免疫療法のためのｔ細胞におけるｃｂｌｂのｃｒｉｓｐｒ−ｃａｓ９編集のための方法、組成物および構成要素
|
|
US12406749B2
(en)
|
2017-12-15 |
2025-09-02 |
The Broad Institute, Inc. |
Systems and methods for predicting repair outcomes in genetic engineering
|
|
WO2019165121A1
(en)
|
2018-02-21 |
2019-08-29 |
Board Of Regents, The University Of Texas System |
Methods for activation and expansion of natural killer cells and uses therof
|
|
CA3093919A1
(en)
*
|
2018-03-15 |
2019-09-19 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
|
AU2019271366B2
(en)
*
|
2018-05-16 |
2026-02-26 |
Research Institute At Nationwide Children's Hospital |
Generation of knock-out primary and expanded human NK cells using Cas9 ribonucleoproteins
|
|
WO2019226953A1
(en)
|
2018-05-23 |
2019-11-28 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
|
CN112368021B
(zh)
|
2018-06-14 |
2025-02-21 |
2赛文缇生物公司 |
Cd79a嵌合抗原受体
|
|
EP3820495A4
(en)
|
2018-07-09 |
2022-07-20 |
The Broad Institute Inc. |
RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
|
|
WO2020072059A1
(en)
|
2018-10-04 |
2020-04-09 |
Bluebird Bio, Inc. |
Cblb endonuclease variants, compositions, and methods of use
|
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
|
EP3884041A2
(en)
|
2018-11-21 |
2021-09-29 |
Indapta Therapeutics, Inc. |
Methods for expansion of natural killer (nk) cell subset and related compositions and methods
|
|
AU2019386140B2
(en)
|
2018-11-28 |
2026-05-28 |
Board Of Regents, The University Of Texas System |
Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
|
|
KR20210116526A
(ko)
*
|
2019-01-16 |
2021-09-27 |
빔 테라퓨틱스, 인크. |
증진된 항-신생물 활성 및 면역억제 내성을 갖는 변형된 면역 세포
|
|
US12351837B2
(en)
|
2019-01-23 |
2025-07-08 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
US12600971B2
(en)
|
2019-02-13 |
2026-04-14 |
Beam Therapeutics Inc. |
Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
|
|
BR112021016046A2
(pt)
*
|
2019-02-15 |
2021-11-09 |
Editas Medicine Inc |
Células assassinas naturais modificadas (nk) para imunoterapia
|
|
WO2020191241A1
(en)
|
2019-03-19 |
2020-09-24 |
The Broad Institute, Inc. |
Methods and compositions for editing nucleotide sequences
|
|
RU2731293C1
(ru)
|
2019-04-12 |
2020-09-01 |
Игорь Петрович Белецкий |
Способ получения генно-модифицированных линий клеток натуральных киллеров с нокаутированным геном PD-1 и повышенной экспрессией белков семейства Фактора Некроза Опухолей для иммунотерапии онкологических заболеваний
|
|
WO2020214842A1
(en)
|
2019-04-17 |
2020-10-22 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
US12594301B2
(en)
|
2019-09-27 |
2026-04-07 |
Beam Therapeutics Inc. |
Compositions and methods for treatment of liquid cancers
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
CN114867485A
(zh)
*
|
2019-10-31 |
2022-08-05 |
全国儿童医院研究所 |
Cd38敲除的原代和扩增的人nk细胞的生成
|
|
CA3177481A1
(en)
|
2020-05-08 |
2021-11-11 |
David R. Liu |
Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
|
|
AU2021347359A1
(en)
|
2020-09-25 |
2023-05-18 |
Beam Therapeutics Inc. |
Fratricide resistant modified immune cells and methods of using the same
|
|
WO2022112596A1
(en)
|
2020-11-30 |
2022-06-02 |
Cellectis Sa |
Use of aminoquinoline compounds for higher gene integration
|
|
EP4255453A4
(en)
*
|
2020-12-03 |
2025-03-26 |
Nkarta, Inc. |
Methods for manipulating immune cells for increased potency and persistence, as well as uses of engineered cells in immunotherapy
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
IL303269A
(en)
|
2020-12-03 |
2023-07-01 |
Century Therapeutics Inc |
Genetically engineered cells and uses thereof
|
|
US20240299542A1
(en)
*
|
2021-01-05 |
2024-09-12 |
City Of Hope |
Natural killer cells engineered to reduce or eliminate cbl-b and uses thereof
|
|
MX2024003887A
(es)
|
2021-10-14 |
2024-07-09 |
Arsenal Biosciences Inc |
Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica.
|
|
JP2024540469A
(ja)
*
|
2021-11-17 |
2024-10-31 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
抑制因子を克服するためのｔ細胞ベースの免疫療法用の遺伝子標的
|
|
WO2023147776A1
(en)
*
|
2022-02-07 |
2023-08-10 |
Hangzhou Qihan Biotechnology Co., Ltd. |
Systems and methods for enhanced immunotherapies
|
|
WO2024073010A1
(en)
*
|
2022-09-28 |
2024-04-04 |
University Of Cincinnati |
Inhibition of natural killer cell cytoxocity
|
|
WO2024124242A2
(en)
*
|
2022-12-09 |
2024-06-13 |
Research Institute At Nationwide Children's Hospital |
Combination cd38ko/car ki nk cell immunotherapy for dual targeting with cd38 monoclonal antibodies
|
|
TW202442689A
(zh)
|
2023-03-03 |
2024-11-01 |
美商亞森諾生物科學公司 |
靶向ｐｓｍａ及ｃａ９之系統
|
|
FI131854B1
(en)
|
2023-05-29 |
2026-01-12 |
Onni Biotechnologies Oy |
Modified natural killer cells with enhanced cytotoxic activity and greater survival
|
|
CN117430721B
(zh)
*
|
2023-10-25 |
2024-06-25 |
北京景达生物科技有限公司 |
Cd123靶向car-nk细胞的制备及其应用
|
|
WO2026060102A1
(en)
*
|
2024-09-11 |
2026-03-19 |
Northeastern University |
Methodology for sorting, expansion, and transcriptomics analysis of killer t-cells
|